Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non–muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
Pietro Scilipoti, Paolo Zaurito, Mattia Longoni, Maurizio Colecchia, Francesco Montorsi, Prof Andrea Salonia, Chiara Mercinelli, Brigida Anna Maiorano, Andrea Necchi, Alberto Briganti, Marco Moschini
Topics & Concepts
MedicineHazard ratioInternal medicineBladder cancerAdverse effectOncologyConfidence intervalRandomized controlled trialMaintenance therapyMeta-analysisBCG vaccineBacillus (shape)Combination therapySurgeryUrologyClinical trialCancerDiseaseRelative riskProportional hazards modelOverall survivalLower riskQuality of life (healthcare)Survival analysisBladder and Urothelial Cancer TreatmentsImmune responses and vaccinationsUrinary and Genital Oncology Studies